Compare LQDA & HOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | HOG |
|---|---|---|
| Founded | 2004 | 1903 |
| Country | United States | United States |
| Employees | N/A | 6400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Motor Vehicles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2020 | 1994 |
| Metric | LQDA | HOG |
|---|---|---|
| Price | $37.80 | $24.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $41.00 | $24.00 |
| AVG Volume (30 Days) | 1.1M | ★ 3.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | $158,320,000.00 | ★ $4,473,175,000.00 |
| Revenue This Year | $278.87 | N/A |
| Revenue Next Year | $57.13 | $3.79 |
| P/E Ratio | ★ N/A | $8.45 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $17.09 |
| 52 Week High | $46.67 | $31.25 |
| Indicator | LQDA | HOG |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 76.67 |
| Support Level | $31.75 | $22.75 |
| Resistance Level | $39.19 | $24.98 |
| Average True Range (ATR) | 2.12 | 0.80 |
| MACD | 0.09 | 0.27 |
| Stochastic Oscillator | 37.52 | 97.56 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 34% of the heavyweight domestic market in 2025.